Illumina News and Research

RSS

Multiplicom launches MID kit for Illumina MiSeq and MASTR kits for MODY, ADH and HCM

Multiplicom NV, a specialist in the development, production and commercialization of innovative molecular genetic tests based on massively parallel sequencing, today announces that it is launching a CE/IVD labeled MID kit for Illumina MiSeq together with three new germline mutation detection MASTRTM kits enabling the identification of individuals at risk for maturity onset diabetes of the young, autosomal dominant hypercholesterolemia, and hypertrophic cardiomyopathy.

2 Dec 2013

Illumina announces launch of TruGenome Undiagnosed Disease Test

Illumina, Inc. today announced the launch of its TruGenome Undiagnosed Disease Test provided by the CLIA-certified, CAP-accredited Illumina Clinical Services Laboratory.

From Illumina, Inc. 22 Oct 2013

U.K. Organizations Partner With Illumina To Sequence 10,000 Whole Genomes

...

From Illumina, Inc. 21 Oct 2013

New collaborative project aims to discover genes underlying rare genetic diseases

...

21 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

Global Genomics Group Enlists Illumina For Cardiovascular Disease Study

...

From Illumina, Inc. 25 Sep 2013

New And Improved Method For Analyzing Single-Cell Gene Expression

...

24 Sep 2013

Researchers develop new, improved technique for single-cell gene expression analysis

A team of researchers affiliated with Ludwig Cancer Research and the Karolinska Institutet in Sweden report in the current issue of Nature Methods a dramatically improved technique for analyzing the genes expressed within a single cell -- a capability of relevance to everything from basic research to future cancer diagn

23 Sep 2013

Genomatix adds Genomatix Pathway System to Illumina's BaseSpace Apps

Genomatix today announced it has added the Genomatix Pathway System (GePS) to BaseSpace Apps, Illumina's dedicated applications store and informatics community dedicated to advancing genomic analysis.

12 Sep 2013

Oxford Gene Technology releases next generation sequencing survey results

Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.

From Oxford Gene Technology 21 Aug 2013

Illumina announces availability of its newest reagent kits for MiSeq benchtop sequencer

Illumina, Inc. today announced the availability of its newest reagent kits for the MiSeq, the industry's most accurate and easiest-to-use benchtop sequencer. The improved chemistry doubles sequencing output to 15 gigabases (Gb) by increasing the number of sequencing reads (up to 25 million reads) and overall read length (up to 2x300 base pairs). These innovations enable researchers to perform new applications including exome sequencing on the MiSeq.

From Illumina, Inc. 19 Aug 2013

Scientists provide insight into emergence of inter-species transmittable viruses

Outbreaks such as the severe acute respiratory syndrome (SARS) Middle East respiratory syndrome coronavirus (MERS) have afflicted people around the world, yet many people think these trends are on the decline.

13 Aug 2013

Verinata Health receives New York's Laboratory Permit for CLIA-certified verifi prenatal test

Illumina, Inc. (NASDAQ: ILMN) today announced that Verinata Health, an Illumina company, received the Clinical Laboratory Permit from the New York State Department of Health for its CLIA-certified, CAP-accredited laboratory.

2 Aug 2013

HistoGenetics selects MiSeq sequencing system from Illumina for use in CLIA laboratory

Illumina, Inc. today announced that HistoGenetics, the leader in high-resolution sequence-based human leukocyte antigen testing services, has selected the MiSeq sequencing system for use in its CLIA laboratory.

From Illumina, Inc. 22 Jul 2013

Teva signs agreement with Verinata Health for commercialization of verifi prenatal test in Israel

Illumina, Inc. today announced that Teva Pharmaceutical Industries Ltd. signed an exclusive agreement with Verinata Health, an Illumina company, for the commercialization of the verifi non-invasive prenatal test in Israel.

1 Jul 2013

Findings provide basis for reinvigoration of research efforts in breast cancer prevention

Genetic variations, known as single nucleotide polymorphisms, in or near the genes ZNF423 and CTSO were associated with breast cancer risk among women who underwent prevention therapy with tamoxifen and raloxifene, according to data published in Cancer Discovery, a journal of the American Association for Cancer Research.

14 Jun 2013

Illumina releases genomics cloud computing and storage platform

Illumina, Inc. today announced the full commercial availability of BaseSpace, the Company's genomics cloud computing and storage platform.

From Illumina, Inc. 16 May 2013

Rare mutation confers high risk of osteoporosis and certain cancers

deCODE genetics (an Amgen subsidiary) and Illumina, global leaders in analyzing and understanding the human genome, together with scientists from the National Hospital of Iceland and the University of Iceland reported today in the journal Nature the identification of a rare nonsense mutation that confers high risk of osteoporosis and osteoporosis related traits.

6 May 2013

Researchers use metagenomics to identify the cause of outbreaks of bacterial infection

Researchers have been able to reconstruct the genome sequence of an outbreak strain of Shiga-toxigenic Escherichia coli (STEC), which caused over 50 deaths in Germany, using an approach known as metagenomics which bypasses the need for growing bacteria in the lab.

12 Apr 2013

Illumina releases TruSight Tumor for NGS-based somatic variant detection in solid tumors

Illumina, Inc. today announced the next product in its TruSight line of content sets, TruSight Tumor, for NGS-based somatic variant detection in solid tumors.

From Illumina, Inc. 4 Apr 2013